PF-08653944 for Obesity

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Pfizer

Must not be taking: GLP-1 receptor agonists

Disqualifiers: Diabetes, Cardiovascular, Hepatic, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 11 weeks

20 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity.

Participants will receive the study medicine for a short period, and doctors will measure how the medicine moves through the stomach and monitor safety. The goal is to better understand how this medicine works in the body and to check for any side effects.

The information from this study may help researchers plan future studies of this medicine.

Who Is on the Research Team?

Pfizer CT.gov Call Center

Principal Investigator

Pfizer

Are You a Good Fit for This Trial?

Inclusion Criteria

My BMI is between 27 and 45, and I weigh more than 50 kg (110 lb).

I am overweight or obese.

I am 18 or older and generally healthy based on recent medical checks.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive multiple SC doses of PF-08653944 and oral doses of acetaminophen to assess gastric emptying

11 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• PF-08653944

How Is the Trial Designed?

Group I: Period 6 Experimental Treatment 2 Interventions

Participants will receive single SC dose of PF-08653944 and single oral dose of acetaminophen.

Group II: Period 5 Experimental Treatment 2 Interventions

Participants will receive SC dose of PF-08653944 and single oral dose of acetaminophen.

Group III: Period 4 Experimental Treatment 1 Intervention

Participants will receive SC dose of PF-0865394.

Group IV: Period 3 Experimental Treatment 1 Intervention

Participants will receive SC dose of PF-0865394.

Group V: Period 2 Experimental Treatment 2 Interventions

Participants will receive SC dose of PF-08653944 and single oral dose of acetaminophen.

Group VI: Period 1 Experimental Treatment 1 Intervention

Participants will receive a single oral dose of acetaminophen.

Who Is Running the Clinical Trial?

Pfizer

Lead Sponsor

Trials

4,712

Recruited

50,980,000+

Known For

Vaccine Innovations

Top Products

Viagra, Zoloft, Lipitor, Prevnar 13

Albert Bourla

Pfizer

Chief Executive Officer since 2019

PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki

Patrizia Cavazzoni

Pfizer

Chief Medical Officer

MD from McGill University